Navin Fluorine International has notified stock exchanges of an analyst and institutional investor meet scheduled for May 22, 2026, at 14:00 IST. The intimation, filed pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was signed by Niraj B. Mankad, President Legal and Company Secretary, on May 18, 2026. Discussions at the meeting will be based on publicly available information, and the accompanying investor presentation has been made available on the company's website.

Q4FY26 and FY26 Consolidated Financial Highlights

The company reported strong consolidated financial results for both Q4FY26 and the full year FY26. Net revenue from operations for Q4FY26 reached Rs. 937.71 Crs, a 34% increase year-on-year, while Operating EBITDA rose 80% YoY to Rs. 321.15 Crs, with an Operating EBITDA Margin of 34.2%—an improvement of 875 basis points over Q4FY25. Operating PBT for Q4FY26 stood at Rs. 250.99 Crs, up 118% YoY. For the full year FY26, consolidated net revenue from operations grew 41% YoY to Rs. 3,313.90 Crs, with Operating EBITDA expanding 103% YoY to Rs. 1,081.68 Crs.

The following table summarises the key consolidated profitability metrics:

Quarterly Revenue Trend — FY26

Consolidated revenues showed consistent sequential growth across all four quarters of FY26. The quarterly revenue progression was as follows: Rs. 725 Crs in Q1FY26, Rs. 758 Crs in Q2FY26, Rs. 892 Crs in Q3FY26, and Rs. 938 Crs in Q4FY26. On an annual basis, revenues grew from Rs. 2,349 Crs in FY25 to Rs. 3,314 Crs in FY26, representing a 41% increase. Operating PBT followed a similar upward trajectory, rising from Rs. 141 Crs in Q1FY26 to Rs. 251 Crs in Q4FY26, with full-year Operating PBT increasing 142% YoY to Rs. 815 Crs. Profit After Tax on a consolidated basis rose 130% YoY from Rs. 289 Crs in FY25 to Rs. 664 Crs in FY26.

Business Vertical Performance

All three business verticals—HPP, Specialty Chemicals, and CDMO—recorded year-on-year revenue growth in FY26. The revenue growth by vertical is summarised below:

Key operational highlights by vertical include:

• HPP: AHF capex commissioned with commercial supply commenced; capex for additional HFC capacity equivalent to up to 15,000 MTPA of R32 is on track for commissioning in Q3FY27; pricing environment for HFC continues to be constructive.
• Specialty Chemicals: Product pipeline described as strong, with scale-up across existing molecules and new launches; Chemours project on track for completion in Q1FY27; de-bottlenecking of MPP capacity at Dahej on track for commissioning in Q3FY27.
• CDMO: European CDMO MSA saw successful completion of validation with commercial supplies started from cGMP4; portfolio described as balanced with a mix of late/commercial and early-stage molecules across therapeutic areas including Oncology, Respiratory, Cardiovascular, Neurology, and Animal Health.

Ongoing Capital Expenditure Programmes

The company has outlined three ongoing capex initiatives, with the HFC capacity expansion targeting commissioning in Q3FY27 and a peak revenue potential of Rs. 600–825 Crs per annum. Details of all capex programmes are presented below:

Standalone Financial Performance

On a standalone basis, net revenue from operations for Q4FY26 was Rs. 626.51 Crs, up 29% YoY, while full-year FY26 standalone revenue stood at Rs. 2,301.84 Crs, a 36% increase over FY25's Rs. 1,686.81 Crs. Standalone Operating EBITDA for FY26 grew 96% YoY to Rs. 663.56 Crs, with an Operating EBITDA Margin of 28.8% compared to 20.1% in FY25—an improvement of 874 basis points. Standalone Profit After Tax for FY26 rose 102% YoY to Rs. 487.67 Crs.

ESG and Governance Highlights

The company reported a total CSR expenditure of Rs. 8.72 Crores for FY26, directed towards multiple social and community welfare organisations. On the environmental front, the Dewas facility increased its renewable electricity share from 14.4% to 21.1%, while 14,429 trees were planted across facilities, helping absorb 289 tCO₂e annually. Total R&D spend for FY25 was reported at Rs. 54.69 crores. The company's board comprises ten directors, including multiple independent directors across statutory committees, and reported no auditor qualifications, no restatements of financial statements, no allegations of financial imprudence, and no defaults on repayments, creditors, or dividends.

Navin Fluorine International has received mixed analyst recommendations, with brokerage firms presenting divergent views on the specialty chemicals company's prospects despite acknowledging its strong operational performance.

Analyst Recommendations Overview

Citigroup's Cautious Stance

Citigroup has assigned a Sell rating with a target price of ₹6,500, expressing concerns over valuation metrics. Despite acknowledging the company's strong EBITDA growth of 80% YoY driven by CDMO ramp-up and capacity additions, the brokerage highlights the rich valuation at approximately 29x FY27E EV/EBITDA. The firm also points to potential R32 pricing pressure amid rising competition, noting the company's high sensitivity to price changes as a limiting factor for further upside.

Positive Outlook from DAM Capital

DAM Capital maintains a Buy rating with a target price of ₹7,769, emphasizing the company's strong all-round performance. The brokerage notes the company's sixth consecutive quarter of growth, supported by robust specialty chemicals and CDMO momentum. Key highlights include the new cGMP-4 plant, HPP strength, and improving utilization with Project Nectar expected to reach 75-80% by FY27. Management guidance of approximately 30% EBITDA margins with better working capital efficiency further supports the positive view.

Jefferies' Bullish Assessment

Jefferies has issued a Buy rating with the highest target price of ₹8,385, citing a strong Q4 performance that exceeded expectations. The brokerage highlights EBITDA and PAT growth of 19% and 30% respectively, driven by Specialty Chemicals and CDMO segments. Jefferies emphasizes multi-year contracts, data center cooling ramp-up, and R32 expansion as factors supporting FY27-28 growth visibility. The company's net-cash balance sheet and approximately 24% EPS CAGR outlook further reinforce the positive recommendation.

Performance Highlights

The company has demonstrated consistent operational strength across multiple parameters:

• Strong EBITDA growth of 80% YoY
• Six consecutive quarters of growth momentum
• Robust CDMO ramp-up and capacity additions
• Q4 beat with significant profit growth
• Multi-year contract visibility providing revenue stability
• Net-cash balance sheet position

The contrasting analyst views reflect the balance between strong operational performance and valuation concerns, with target prices varying significantly based on different assessment methodologies and risk perspectives.